What we do

Educational Resources

Subscribe to
our newsletter!

Educational clips

Name: Mental Health and psychosocial support with myeloma
Uploaded: 2026-08-14T06:35:01Z
Description: Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, Psychotherapy Service, Haemato-Oncology, King's College Hospital NHS Foundation Trust shares

Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, Psychotherapy Service, Haemato-Oncology, King's College Hospital NHS Foundation Trust shares

Now Playing

Mental Health and psychosocial support with myeloma

Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, ...

Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, Psychotherapy Service, Haemato-Oncology, King's College Hospital NHS Foundation Trust shares

Now Playing

Understanding cure in myeloma

What does “cure” look like in myeloma? Professor Philippe Moreau, ...

What does “cure” look like in myeloma?

Professor Philippe Moreau, President of the International Myeloma Society, and Head of Haematology at the University Hospital of Nantes, France explains the emerging ...concept of cure, why experts believe it is now appropriate to discuss it, and what it could mean for people living with myeloma.

He discusses how advances in treatment, particularly newer immunotherapies used alongside established approaches such as autologous stem cell transplantation, have dramatically improved patient outcomes. The conversation explores the proposed international consensus definition of a cure, including the importance of being off treatment and maintaining minimal residual disease (MRD) negativity for at least five years.

Professor Moreau also explains:

Why sustained MRD negativity is considered a key indicator of long-term disease control

Which treatment approaches may make a cure possible

Why access to the latest therapies varies between countries and affects patient outcomes

Which patients are currently most likely to achieve a cure

Why doctors emphasise hope while recognising that not every patient will achieve the same outcomes

The interview concludes by discussing how continuing advances in myeloma treatment are bringing life expectancy for some patients closer to that of the general population.

Please note: This interview reflects current expert opinion and emerging evidence. A cure is not yet achievable for everyone with myeloma, and treatment decisions should always be discussed with your healthcare team.

0:00 (Understanding cure in myeloma)
1:29 (Can we currently cure myeloma?)
2.51 (How are experts defining cure in myeloma?)
3:41 (Which treatments might help a cure?)
5:55 (Which patients could potentially be cured?)Show More

$EHA 2026 | Linker-AL2 study: linvoseltamab monotherapy in relapsed or refractory AL amyloidosis$

Now Playing

EHA 2026 | Linker-AL2 study: linvoseltamab monotherapy in relapsed or refractory AL amyloidosis

Dr Ashutosh Wechalekar, University College London Hospital and ...

Dr Ashutosh Wechalekar, University College London Hospital and National Amyloidosis Center, explains the early efficacy and safety results from the phase I/II LINKER AL2 clinical trial. This trial shows promising ...results for the BCMA bispecific antibody linvoseltamab in patients with relapsed or refractory AL amyloidosis.

0:00 (Watch now)
0:11 (What is linvoseltamab?)
1:18 What is the LINKER-AL2 trial?)
3:11 (What does it means for patients?)Show More

Now Playing

EHA 2026 CARES phase 3 clinical trial

Dr. Ashutosh Wechalekar, University College London Hospitals, results ...

Dr. Ashutosh Wechalekar, University College London Hospitals, results from the phase III CARES clinical trial show a survival benefit of adding the amyloid depleter anselamimab (also known as CAEL-101) to ...standard treatments in patients with newly diagnosed stage IIIa and IIIb AL amyloidosis.Show More

Now Playing

EHA 2026 CaMMouflage phase 1 clinical trial

Dr. Binod Dhakal, Medical College of Wisconsin, Milwaukee, USA talks ...

Dr. Binod Dhakal, Medical College of Wisconsin, Milwaukee, USA talks to MPE at EHA 2026 about the results of the phase 1 clinical trial known as CaMMouflage. This trial shows ...the safety and preliminary efficacy of the allogeneic anti-BCMA CAR T-cell therapy CB-011 in patients with relapsed or refractory myeloma.

0:00 (What our interview)
0:11 (What is CB-011?)
1:04 (About the CaMMouflage trial)
2:10 (Trial Results)
3:54 (What does this mean for patients?)Show More

Now Playing

EHA 2026 SUCCESSOR-2 clinical trial

MPE interviewed Dr. Alberto Orial, Institut Català d'Oncologia in ...

MPE interviewed Dr. Alberto Orial, Institut Català d'Oncologia in Germans Trias i Pujol Hospital, who explains the results of the late breaking abstract SUCCESSOR-2 evaluating mezigdomide, carfilzomib and dexamethasone (mezikd) ...vs carfilzomib and dexamethasone (kd) in relapsed/refractory myeloma.

0:00 (Watch our interview)
0:11 (What is mezigdomide)
1:00 (What is the SUCCESSOR-2 trial)
1:44 (What are the main results)
3:00 (What do these findings mean for relapsed/refactory myeloma patients)Show More

Now Playing

EHA 2026 MONUMENTAL-3 clinical trial

MPE interviewed Dr. Albert Oriol, Institut Català d'Oncologia in ...

MPE interviewed Dr. Albert Oriol, Institut Català d'Oncologia in Germans Trias i Pujol Hospital, who explains the results of the MONUMENTAL-3 trial for relapsed/refractory myeloma patients, at EHA 2026.

0:00 (Watch ...now)
0:13 (What is talquetamab?)
1:16 (What is the MONUMENTAL-3 trial investigating and why?)
2:30 (What are the key results, including benefits and side effects?)
4:35 (What do these findings mean for relapsed/refactory myeloma patients?)Show More

Now Playing

MajesTEC-9 clinical trial

Dr. Cyrille Touzeau talks through the results from the phase III ...

Dr. Cyrille Touzeau talks through the results from the phase III MajesTEC-9 clinical trial and explains the benefits of teclistamab monotherapy compared with standard of care combinations in patients with ...relapsed or refractory myeloma.Show More

Now Playing

EHA2026 | EMN34 clinical trial

Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains ...

Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains for MPE, the results of the phase 2 ERASMM (EMN34) study, which evaluates safety and efficacy of elranatamab as early intervention ...in patients with high-risk smoldering myeloma.

0:00 (Watch now)
0:10 (What is elranatamab? How is it given and what should patients know about its current and potential uses?)
0:18 (What is the ERASMM (EMN34) trial investigating and what are its main results?)Show More

Now Playing

Can you travel with multiple myeloma?

Can you travel with multiple myeloma? People living with myeloma still ...

Can you travel with multiple myeloma?

People living with myeloma still travel for work, family visits, or holidays. In this video, Dr Charlotte Pawlyn, Haematologist and Cancer Research UK Clinician, discusses ...some important things to consider before you travel to help you stay safe and enjoy your trip.

Topics covered include:
• speaking with your doctor or specialist nurse before travelling
• researching your destination, including vaccines, medical facilities, and emergency contacts
• planning medicines and treatments you may need when travelling
• getting travel insurance
• reducing your risk of infection while away
• knowing when to seek medical help

With some planning and simple precautions, many people with myeloma can continue to travel safely and enjoy their travel experiences.

Chapters

0:00 (Travelling with myeloma)
0:10 (What should someone with myeloma think about when planning a trip?)
1:43 (How can myeloma and its treatments affect infection risk when travelling and what simple precautions can help reduce it?)
3:14 (Before travelling abroad, what should patients know about vaccines, taking medicines and health risks in the country they are visiting?)
4:27 (During travel, what practical things can patients do to stay healthy?)
5:23 (What early signs should patients watch for, and when should they seek medical help?)Show More

Now Playing

About Linvoseltamab

Dr. Xavier Leleu explains what Linvoseltamab is, how it's administered ...

Dr. Xavier Leleu explains what Linvoseltamab is, how it's administered and some of the side effects.

Now Playing

Dr Charlotte Pawlyn on managing infections

Dr Charlotte Pawlyn explains how patients can help protect themselves ...

Dr Charlotte Pawlyn explains how patients can help protect themselves with up-to-date vaccines and some treatment-specific measures.

What we do

Subscribe toour newsletter!

Educational clips

PopUp

Subscribe to
our newsletter!